Peptides - Compound guides
Retatrutide
Retatrutide is an investigational triple GLP-1, GIP and glucagon receptor agonist studied in phase 2 and phase 3 obesity trials. It is not approved as a medicine anywhere.
Retatrutide is a synthetic peptide designed to activate three different hormone receptors at once: the GLP-1 receptor, the GIP receptor and the glucagon receptor. It belongs to a family of molecules built by modifying the natural gut hormone sequences so they resist rapid breakdown in the bloodstream and stay active far longer than the hormones they imitate. Where earlier drugs in this family engaged one or two of these receptors, retatrutide was engineered to engage all three, on the theory that combining appetite suppression with an increase in energy expenditure would produce a larger metabolic effect than either alone.
The most important fact about retatrutide is a regulatory one rather than a scientific one. It is an investigational drug. It has completed phase 2 testing and is currently in phase 3 trials, and it has not been approved by any medicines regulator in the world. Everything written below describes findings from controlled clinical trials conducted under medical supervision, not a product that any person can lawfully be supplied with outside those trials.
How it works
GLP-1 and GIP are incretins - hormones released by cells in the wall of the small intestine when food arrives. Their normal job is to tell the rest of the body that a meal is on its way. They prompt the pancreas to release insulin in proportion to how much glucose is actually present, which is why incretin signalling raises insulin only when it is needed. GLP-1 also suppresses glucagon release after eating, slows the rate at which the stomach empties, and acts on appetite centres in the hypothalamus and brainstem to produce the sensation of fullness. GIP contributes to insulin release and appears to influence how fat tissue handles incoming nutrients.
A receptor agonist is simply a molecule that binds a receptor and switches it on in the same way the natural hormone would. Retatrutide switches on the GLP-1 and GIP receptors, producing the appetite and gastric emptying effects described above, and additionally switches on the glucagon receptor. Glucagon is usually thought of as the hormone that raises blood sugar, but sustained glucagon receptor activation in the liver also increases energy expenditure and drives the breakdown of stored fat. Combining glucagon receptor activity with strong incretin activity is the design idea: the incretin arms reduce how much a person eats while the glucagon arm is intended to increase how much energy the body burns, with the incretin effect on insulin offsetting glucagon's tendency to raise glucose.
What the research actually shows
The trial that brought retatrutide to wide attention was a phase 2 randomised, double-blind, placebo-controlled study in adults with obesity, published in the New England Journal of Medicine in 2023. Participants were randomly assigned to placebo or to one of several retatrutide dose groups and followed for 48 weeks, with change in body weight as the primary measure. The trial reported greater reductions in body weight in the retatrutide groups than in the placebo group over the 48-week study period. Phase 2 trials are designed to detect a signal and to identify a dose range for further study; they are not designed to establish how large or how durable an effect ultimately is. A companion phase 2 trial examined retatrutide in adults with type 2 diabetes and measured change in HbA1c, a marker of average blood glucose over roughly three months, alongside weight.
These are genuine randomised human data, and that is worth stating clearly - retatrutide is not a compound resting on cell culture or rodent work. But phase 2 trials are designed to find a signal and identify a dose range, not to establish long-term safety. They enrol relatively small numbers of carefully selected people for a limited period. The phase 3 programme now underway is the stage at which larger populations, longer exposure and harder clinical endpoints are assessed, and until those trials report and are reviewed by regulators, the balance of benefit and risk for retatrutide is genuinely unknown.
Risks, side effects and what is still unknown
- Gastrointestinal effects are the most frequently reported adverse events across this drug class in trials - nausea, vomiting, diarrhoea and constipation - and in the retatrutide phase 2 trial these were dose-related and were the common reason participants stopped treatment.
- Increases in heart rate have been observed with incretin-based drugs, and glucagon receptor activation raises additional questions about effects on the heart and on liver enzymes that longer trials are designed to answer.
- Pancreatitis, gallbladder disease and thyroid C-cell tumour findings in rodents are the labelled concerns carried by the licensed GLP-1 class, and there is no basis for assuming an investigational triple agonist is free of them.
- Weight lost through appetite suppression is not purely fat. Studies across this class consistently show that a meaningful share of the weight lost is lean mass, including muscle, which matters for strength, metabolic health and long-term function.
- Weight regain after stopping has been documented repeatedly for incretin drugs. The physiological drivers of appetite return when the drug is withdrawn.
- Long-term safety for retatrutide is simply not established. There is no multi-year human safety record, no cardiovascular outcomes data, and no regulatory review of the full dossier. Anyone describing its safety profile as known is going beyond the evidence.
Legal status in the UK
Retatrutide is not approved by the MHRA, the European Medicines Agency or the US Food and Drug Administration. It is an investigational drug, and the only lawful route by which a person in the UK receives it is as a participant in an authorised clinical trial, under medical supervision, with the drug supplied by the trial sponsor.
That means anything sold online, by any seller, labelled as retatrutide sits entirely outside the regulated medicines supply chain. There is no assurance of identity, purity, sterility or dose. Nobody has verified that the vial contains what the label says, that it contains it in the stated amount, or that it is free of contamination. Material sold with a "research use only" or "not for human consumption" label is not thereby made safe or lawful to use in a person - that wording is a disclaimer, not a quality standard. Retatrutide is also a prohibited substance in sport under World Anti-Doping Agency rules for athletes subject to testing.
This page is educational information about an unapproved investigational drug and is not medical advice. Retatrutide is not licensed as a medicine anywhere in the world and is available lawfully only within a clinical trial. Nothing here is a suggestion to obtain or use it. Questions about weight, metabolic health or any treatment belong with a qualified healthcare professional such as your GP.
Metabolic and incretin compounds
Start with the overview: How research peptides are grouped into families
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
